Classification, diagnosis, and differential diagnosis of multiple sclerosis

Current Opinion in Neurology

Volumn 28, Issue 3, 2015, Pages 193-205

  Sand, Ilana Katz ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Classification; diagnosis; differential diagnosis; multiple sclerosis; phenotype

Indexed keywords

ALGORITHM; BRAIN STEM; CLINICAL FEATURE; COGNITIVE DEFECT; DEMYELINATING DISEASE; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; HUMAN; LUMBAR PUNCTURE; MEDICAL HISTORY; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NERVE CELL; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PHENOTYPE; REVIEW; SPINAL CORD; SPINAL CORD DISEASE; CLASSIFICATION;

DIAGNOSIS, DIFFERENTIAL; HUMANS; MULTIPLE SCLEROSIS;

EID: 84929459852     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000206     Document Type: Review

References (78)

1. Belbasis L, Bellou V, Evangelou E, et al. Environmental risk factors and multiple sclerosis: An umbrella review of systematic reviews and metaanalyses. Lancet Neurol 2015; 14:263-273.
2. Sawcer S, Franklin RJ, Ban M. Multiple sclerosis genetics. Lancet Neurol 2014; 13:700-709.
3. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis. Neurology 1996; 46:907-911.
4. Kuceyeski AF, Vargas W, Dayan M, et al. Modeling the relationship among gray matter atrophy, abnormalities in connecting white matter, and cognitive performance in early multiple sclerosis. AJNR Am J Neuroradiol 2015; 36:702-709.
5. Rojas JI, Patrucco L, Miguez J, et al. Brain atrophy in radiologically isolated syndromes. J Neuroimaging 2015; 25:68-71.
6. Biberacher V, Boucard CC, Schmidt P, et al. Atrophy and structural variability of the upper cervical cord in early multiple sclerosis. Mult Scler 2014; doi: 1352458514546514.
7. Nygaard GO, Walhovd KB, Sowa P, et al. Cortical thickness and surface area relate to specific symptoms in early relapsing-remitting multiple sclerosis. Mult Scler 2015; 21:402-414.
8. Perez-Miralles F, Sastre-Garriga J, Tintore M, et al. Clinical impact of early brain atrophy in clinically isolated syndromes. Mult Scler 2013; 19:1878-1886.
9. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology 2014; 83:278-286.
10. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69:292-302.
11. Rovira A, Swanton J, Tintore M, et al. A single, early magnetic resonance imaging study in the diagnosis of multiple sclerosis. Arch Neurol 2009; 66:587-592.
12. Swanton JK, Rovira A, Tintore M, et al. MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: A multicentre retrospective study. Lancet Neurol 2007; 6:677-686.
13. Montalban X, Tintore M, Swanton J, et al. MRI criteria for MS in patients with clinically isolated syndromes. Neurology 2010; 74:427-434.
14. Tur C, Tintore M, Rovira A, et al. Very early scans for demonstrating dissemination in time in multiple sclerosis. Mult Scler 2008; 14:631-635.
15. Brownlee WJ, Swanton JK, Altmann DR, et al. Earlier and more frequent diagnosis of multiple sclerosis using the McDonald criteria. J Neurol Neurosurg Psychiatry 2014; doi: jnnp-2014-308675.
16. Tintore M, Rovira A, Rio J, et al. Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology 2006; 67:968-972.
17. O'Riordan JI, Thompson AJ, Kingsley DP, et al. The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up. Brain 1998; 121 (Pt 3):495-503.
18. Kuhle J, Disanto G, Dobson R, et al. Conversion from clinically isolated syndrome to multiple sclerosis: a large multicentre study. Mult Scler 2015; doi: 1352458514568827.
19. Miller AE, Wolinsky JS, Kappos L, et al. Oral teriflunomide for patients with a first clinical episode suggestive of multiple sclerosis (TOPIC): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014; 13:977-986.
20. Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebocontrolled trial. Lancet 2009; 374:1503-1511.
21. Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001; 357:1576-1582.
22. Filippi M, Rovaris M, Inglese M, et al. Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet 2004; 364:1489-1496.
23. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007; 370:389-397.
24. Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS study group. N Engl J Med 2000; 343:898-904.
25. Dobson R, Ramagopalan S, Davis A, Giovannoni G. Cerebrospinal fluid oligoclonal bands in multiple sclerosis and clinically isolated syndromes: A meta-analysis of prevalence, prognosis and effect of latitude. J Neurol Neurosurg Psychiatry 2013; 84:909-914.
26. Rossi S, Motta C, Studer V, et al. Subclinical central inflammation is risk for RIS and CIS conversion to MS. Mult Scler 2015; doi: 1352458514564482. [Epub ahead of print]
27. Canto E, Tintore M, Villar L, et al. Validation of semaphorin 7A and ala-ss-hisdipeptidase as biomarkers associated with the conversion from clinically isolated syndrome to multiple sclerosis. J Neuroinflammation 2014; 11:181.
28. Villar LM, Espinõ M, Costa-Frossard L, et al. High levels of cerebrospinal fluid free kappa chains predict conversion to multiple sclerosis. Clinica Chimica Acta 2012; 413:1813-1816.
29. Fialová L, Bartos A, S ? varcová J, et al. Serum and cerebrospinal fluid light neurofilaments and antibodies against them in clinically isolated syndrome and multiple sclerosis. J Neuroimmunol 2013; 262:113-120.
30. Martinelli V, Dalla Costa G, Colombo B, et al. Vitamin D levels and risk of multiple sclerosis in patients with clinically isolated syndromes. Mult Scler 2014; 20:147-155.
31. Perez-Rico C, Ayuso-Peralta L, Rubio-Perez L, et al. Evaluation of visual structural and functional factors that predict the development of multiple sclerosis in clinically isolated syndrome patients. Invest Ophthalmol Vis Sci 2014; 55:6127-6131.
32. Wottschel V, Alexander DC, Kwok PP, et al. Predicting outcome in clinically isolated syndrome using machine learning. Neuroimage Clin 2014; 7:281-287.
33. Okuda DT, Mowry EM, Beheshtian A, et al. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology 2009; 72:800-805.
34. Barkhof F, Filippi M, Miller DH, et al. Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997; 120 (Pt 11):2059-2069.
35. Okuda DT, Siva A, Kantarci O, et al. Radiologically isolated syndrome: 5-year risk for an initial clinical event. PLoS One 2014; 9:e90509.
36. Rovaris M, Confavreux C, Furlan R, et al. Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol 2006; 5:343-354.
37. Sand IK, Krieger S, Farrell C, Miller AE. Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis. Mult Scler 2014; 20:1654-1657.
38. Pasquali L, Lucchesi C, Pecori C, et al. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis. J Neuroimmunol 2015; 278:53-59.
39. Iwanowski P, Losy J. Immunological differences between classical phenothypes of multiple sclerosis. J Neurol Sci 2015; 349:10-14.
40. Dickens AM, Larkin JR, Griffin JL, et al. A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis. Neurology 2014; 83:1492-1499.
41. Zastepa E, Fitz-Gerald L, Hallett M, et al. Naive CD4 T-cell activation identifies MS patients having rapid transition to progressive MS. Neurology 2014; 82:681-690.
42. Lavorgna L, Bonavita S, Ippolito D, et al. Clinical and magnetic resonance imaging predictors of disease progression in multiple sclerosis: a nine-year follow-up study. Mult Scler 2014; 20:220-226.
43. Paling D, Solanky BS, Riemer F, et al. Sodium accumulation is associated with disability and a progressive course in multiple sclerosis. Brain 2013; 136 (Pt 7):2305-2317.
44. Thorpe JW, Kidd D, Moseley IF, et al. Serial gadolinium-enhanced MRI of the brain and spinal cord in early relapsing-remitting multiple sclerosis. Neurology 1996; 46:373-378.
45. Pandey KS, Krieger SC, Farrell C. Clinical course in multiple sclerosis patients presenting with a history of progressive disease. Multiple Sclerosis Relat Dis 2014; 3:67-71.
46. Cree BA. Acute inflammatory myelopathies. Handb Clin Neurol 2014; 122:613-667.
47. Bourre B, Zephir H, Ongagna JC, et al. Long-term follow-up of acute partial transverse myelitis. Arch Neurol 2012; 69:357-362.
48. Miller DH, Leary SM. Primary-progressive multiple sclerosis. Lancet Neurol 2007; 6:903-912.
49. Weisfeld-Adams JD, Katz Sand IB, Honce JM, Lublin FD. Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis. Brain 2015; 138:517-539.
50. Petzold A, Wattjes MP, Costello F, et al. The investigation of acute optic neuritis: a review and proposed protocol. Nat Rev Neurol 2014; 10:447-458.
51. The clinical profile of optic neuritis. experience of the optic neuritis treatment trial. optic neuritis study group. Arch Ophthalmol 1991; 109:1673-1678.
52. Bermel RA, Balcer LJ. Optic neuritis and the evaluation of visual impairment in multiple sclerosis. Continuum (Minneap Minn) 2013; 19:1074-1086.
53. Hickman SJ, Dalton CM, Miller DH, Plant GT. Management of acute optic neuritis. Lancet 2002; 360:1953-1962.
54. Petzold A, Pittock S, Lennon V, et al. Neuromyelitis optica-IgG (aquaporin-4) autoantibodies in immune mediated optic neuritis. J Neurol Neurosurg Psychiatry 2010; 81:109-111.
55. Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes. Lancet Neurol 2012; 11:157-169.
56. Calabrese M, Gajofatto A, Gobbin F, et al. Late-onset multiple sclerosis presenting with cognitive dysfunction and severe cortical/infratentorial atrophy. Mult Scler 2015; 21:580-589.
57. Rae-Grant AD. Unusual symptoms and syndromes in multiple sclerosis. Continuum (Minneap Minn) 2013; 19:992-1006.
58. Katz Sand IB, Lublin FD. Diagnosis and differential diagnosis of multiple sclerosis. Continuum (Minneap Minn) 2013; 19:922-943.
59. Tartaglino LM, Friedman DP, Flanders AE, et al. Multiple sclerosis in the spinal cord: MR appearance and correlation with clinical parameters. Radiology 1995; 195:725-732.
60. Flanagan EP, Weinshenker BG, Krecke KN, et al. Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders. JAMA Neurol 2015; 72:81-87.
61. Storoni M, Davagnanam I, Radon M, et al. Distinguishing optic neuritis in neuromyelitis optica spectrum disease from multiple sclerosis: a novel magnetic resonance imaging scoring system. J Neuroophthalmol 2013; 33:123-127.
62. Khanna S, Sharma A, Huecker J, et al. Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis. J Neuroophthalmol 2012; 32:216-220.
63. Kitley J, Leite MI, Nakashima I, et al. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 2012; 135 (Pt 6):1834-1849.
64. Fernandes DB, Ramos Rde I, Falcochio C, et al. Comparison of visual acuity and automated perimetry findings in patients with neuromyelitis optica or multiple sclerosis after single or multiple attacks of optic neuritis. J Neuroophthalmol 2012; 32:102-106.
65. Bennett J, de Seze J, Lana-Peixoto M, et al. Neuromyelitis optica and multiple sclerosis: seeing differences through optical coherence tomography. Mult Scler 2015; doi: 1352458514567216.
66. Viegas S, Weir A, Esiri M, et al. Symptomatic, radiological and pathological involvement of the hypothalamus in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2009; 80:679-682.
67. Takai Y, Misu T, Nakashima I, et al. Two cases of lumbosacral myeloradiculitis with antiaquaporin-4 antibody. Neurology 2012; 79:1826-1828.
68. Guo Y, Lennon VA, Popescu BF, et al. Autoimmune aquaporin-4 myopathy in neuromyelitis optica spectrum. JAMA Neurol 2014; 71: 1025-1029.
69. Suzuki N, Takahashi T, Aoki M, et al. Neuromyelitis optica preceded by hyperCKemia episode. Neurology 2010; 74:1543-1545.
70. Magana SM, Matiello M, Pittock SJ, et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009; 72:712-717.
71. Cheng C, Jiang Y, Chen X, et al. Clinical, radiographic characteristics and immunomodulating changes in neuromyelitis optica with extensive brain lesions. BMC Neurol 2013; 13:72.
72. Clardy SL, Lucchinetti CF, Krecke KN, et al. Hydrocephalus in neuromyelitis optica. Neurology 2014; 82:1841-1843.
73. Kim W, Kim SH, Huh SY, Kim HJ. Brain abnormalities in neuromyelitis optica spectrum disorder. Mult Scler Int 2012; 2012:735486.
74. Huh SY, Min JH, Kim W, et al. The usefulness of brain MRI at onset in the differentiation of multiple sclerosis and seropositive neuromyelitis optica spectrum disorders. Mult Scler 2014; 20:695-704.
75. Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011; 306:82-90.
76. Ebers GC, Paty DW. CSF electrophoresis in one thousand patients. Can J Neurol Sci 1980; 7:275-280.
77. Eshaghi A, Riyahi-Alam S, Saeedi R, et al. Classification algorithms with multimodal data fusion could accurately distinguish neuromyelitis optica from multiple sclerosis. Neuroimage Clin 2015; 7:306-314.
78. Pittock SJ, Debruyne J, Krecke KN, et al. Chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). Brain 2010; 133:2626-2634.